Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Apr 18, 2025
  • participants needed
    120
  • sponsor
    Pfizer
Send
Updated on 4 October 2022
See if I qualify
combination therapy
monoclonal antibodies
measurable disease
growth factor
programmed cell death 1 ligand 1

Summary

This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and expansion study intended to evaluate the safety, viral load kinetics and shedding, pharmacodynamic, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally advanced or metastatic solid tumors who have exhausted all available standard of care therapies available to them.

The study consists of 2 parts: Part 1 dose escalation for PF-07263689 monotherapy (Part 1A) and in combination with sasanlimab (Part 1B), followed by Part 2 dose expansion for the combination therapy.

Details
Condition Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Treatment Sasanlimab, PF-07263689
Clinical Study IdentifierNCT05061537
SponsorPfizer
Last Modified on4 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Histological or cytological diagnosis of locally advanced or metastatic solid tumors known to have approved therapies using immune checkpoint inhibitors or anti-vascular endothelial growth factor agents
Have exhausted (or refuse) all available standard of care therapy (e.g., including anti-PD1/programmed death ligand 1 [PDL1] if applicable) or for whom no standard therapy is available for their tumor type
Patients with prior anti-PD1/PDL1 must have documentation of primary or secondary resistance to last prior anti-PD1/PDL1 therapy according to Immunotherapy Resistance Committee (SITC) (Kluger et al, 2020)
Have at least 1 measurable lesion by RECIST 1.1 that has not been previously irradiated (for Part 2 only)
Have recently obtained archival tumor tissue sample available, or undergo de novo tumor biopsy
Eastern Cooperative Oncology Group (ECOG) PS 0-1
Adequate hematologic, renal, and liver functions
Dose Escalation (Part 1A and 1B): Any advanced or metastatic solid tumor fulfilling other relevant eligibility criteria
Dose Expansion (Part 2): Tumor specific cohorts (NSCLC, RCC, melanoma, MSS CRC) must have received prior approved therapies (Part 2)

Exclusion Criteria

Other active malignancy
Recent major surgery
Systemic anticancer therapy and chemotherapy within protocol-defined washout period
Known or suspected hypersensitivity to prior treatment with any vaccinia oncolytic, pox virus, or antiviral agents within the past 10 years
Current or history of myocarditis or congestive heart failure (New York Heart Association [NYHA] III-IV); unstable angina; or serious uncontrolled arrhythmia or recent myocardial infarction
Active or history of interstitial lung disease (ILD)/pneumonitis
Patients requiring chronic systemic immunosuppressants
History of severe immune mediated side effect that was considered related to prior immune modulatory therapy and requiring immunosuppressive therapy
Known symptomatic brain metastases requiring steroids
History of or ongoing severe inflammatory skin conditions or severe eczema having required medical treatment
Any prior or planned organ transplant
Presence of any open, active wound requiring treatment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

combination therapy
monoclonal antibodies
measurable disease
growth factor
programmed cell death 1 ligand 1

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note